Peptidase Inhibition and Analysis
Peptidase Inhibition and Analysis is a research topic within Oncology. Science Explorer counts 57k research works in it since 1950. 18.9% of them reached the world's top 10% most cited for their field and year.
This cluster of papers explores the role of fibroblast activation in cancer progression, focusing on the expression of fibroblast activation protein, immunosuppression in the tumor microenvironment, N-terminal acetylation of proteins, protease inhibitors for cancer therapy, angiogenesis, and PET imaging to target stromal cells in the tumor microenvironment.
- Fibroblast Activation Protein
- Tumor Microenvironment
- Immunosuppression
- Cancer Therapy
- N-terminal Acetylation
- Protease Inhibitors
- Angiogenesis
- PET Imaging
- Stromal Cells
- Tumor Stroma
- Research works
- 57k fractional, since 1950
- In the world top 10%
- 11k per year above
- Top-10% rate
- 18.9% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +17% the tick is no change
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead Peptidase Inhibition and Analysis research?
By volume, China and the United States publish the most (2.9k and 1.9k works in 2022–2025).
By volume, 2022–2025
- 1 China 2.9k works
- 2 United States 1.9k works
- 3 Germany 471 works
- 4 India 450 works
- 5 Japan 412 works
- 6 United Kingdom 301 works
- 7 Italy 288 works
- 8 France 217 works
- 9 South Korea 204 works
- 10 Spain 191 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Peptidase Inhibition and Analysis research?
By volume in 2022–2025, Chinese Academy of Medical Sciences & Peking Union Medical College publishes the most Peptidase Inhibition and Analysis research, followed by Sun Yat-sen University and Sichuan University.
By volume, 2022–2025
- 1 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 65 works
- 2 Sun Yat-sen UniversityChina 49 works
- 3 Sichuan UniversityChina 40 works
- 4 The University of Texas MD Anderson Cancer CenterUnited States 40 works
- 5 Shanghai Jiao Tong UniversityChina 39 works
- 6 Peking UniversityChina 38 works
- 7 Harvard UniversityUnited States 31 works
- 8 Nanjing Medical UniversityChina 30 works
- 9 Chinese Academy of SciencesChina 28 works
- 10 Zhejiang UniversityChina 27 works
Who are the leading researchers in Peptidase Inhibition and Analysis?
The most-cited researchers publishing on Peptidase Inhibition and Analysis include Dirk Schadendorf.
- 1 Dirk Schadendorf Germany 4.4k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Peptidase Inhibition and Analysis research done?
The largest centres of Peptidase Inhibition and Analysis research in 2022–2025 are Beijing (China), Shanghai (China), Guangzhou (China) and Nanjing (China). Among places with at least 20 works in it, it is an unusually large share of all research in Luzhou and Heidelberg.
Largest cities, 2022–2025
Where it is the local speciality
- LuzhouCN · 51.8 works24×
- HeidelbergDE · 51.8 works5.7×
Location quotient: how much more of its research is in Peptidase Inhibition and Analysis than the world average.
Where is the best place to study Peptidase Inhibition and Analysis?
Among universities, judged by research, China Pharmaceutical University, Chinese Academy of Medical Sciences & Peking Union Medical College and Shenyang Pharmaceutical University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | China Pharmaceutical UniversityChina | 68.7 | 40.1% | 13.9× | 26 | +14.0% |
| 2 | Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina | 59.0 | 23.8% | 7.6× | 65 | -0.0% |
| 3 | Shenyang Pharmaceutical UniversityChina | 58.5 | 23.7% | 9.7× | 11 | +330.9% |
| 4 | Mashhad University of Medical SciencesIran | 57.2 | 20.2% | 8.7× | 18 | +160.8% |
| 5 | Southern Medical UniversityChina | 56.0 | 36.3% | 7.0× | 22 | -1.3% |
| 6 | Guangzhou Medical UniversityChina | 53.8 | 28.0% | 7.5× | 18 | +71.8% |
| 7 | Second Military Medical UniversityChina | 50.8 | 25.0% | 14.7× | 15 | -13.8% |
| 8 | Heidelberg UniversityGermany | 50.1 | 28.9% | 4.6× | 21 | +28.8% |
| 9 | Shandong First Medical UniversityChina | 49.4 | 22.5% | 9.0× | 20 | -8.6% |
| 10 | Zhengzhou UniversityChina | 49.0 | 29.7% | 2.8× | 21 | +159.2% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Peptidase Inhibition and Analysis research growing?
Output in 2018–2022 was 17% higher than in 2013–2017, peaking in 2025. The fastest-growing topics are Peptidase Inhibition and Analysis.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.